ストックスクリーナーアプリを入手
33.42
0.45%
-0.15
アフターアワーズ：
32.99
-0.43
-1.29%
Capricor Therapeutics Inc (CAPR) 最新ニュース
Is It Too Late To Consider Capricor Therapeutics (CAPR) After Strong Multi Year Share Gains? - simplywall.st
Capricor Therapeutics’ DMD Treatment Study Shows Improvement In Key Heart Function Measures - Asianet Newsable
Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire
Capricor Therapeutics (CAPR) Reveals Promising Data from Phase 3 HOPE-3 Trial - GuruFocus
Capricor earnings on deck after FDA resumes deramiocel review By Investing.com - Investing.com Nigeria
CAPR Stock In Focus: Capricor Says Phase 3 DMD Trial Shows Cardiac Improvement With Deramiocel - Stocktwits
Capricor earnings on deck after FDA resumes deramiocel review - Investing.com UK
Capricor Therapeutics Announces Late-Breaking HOPE-3 Data - GlobeNewswire
Capricor Therapeutics Hits Day High with 8.06% Surge in Stock Price - Markets Mojo
Capricor Therapeutics (CAPR) Set to Announce Q4 Earnings - GuruFocus
CAPR Stock Surged 17% Today — What’s Fueling The Rally? - Stocktwits
Capricor Therapeutics Hits Day High with Strong 9.04% Intraday Surge - Markets Mojo
FDA resumes review of Capricor’s cell therapy deramiocel - The Pharma Letter
Capricor Therapeutics Hits Day High with Strong 9.78% Intraday Surge - Markets Mojo
Capricor Therapeutics Opens with 10.29% Gain, Outperforming S&P 500's 0.83% Rise - Markets Mojo
FDA resumes review of Capricor’s Deramiocel for DMD treatment By Investing.com - Investing.com Canada
Capricor Therapeutics (CAPR) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
H.C. Wainwright Maintains Buy on Capricor Therapeutics, Inc. (CAPR) Mar 2026 - Meyka
Why Capricor Therapeutics (CAPR) Is Up 29.3% After FDA Resumes Review of Deramiocel BLA - simplywall.st
Capricor Therapeutics (CAPR) Surges as FDA Reviews Key Therapy - GuruFocus
What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday? - Sahm
Capricor Therapeutics Inc expected to post a loss of 54 cents a shareEarnings Preview - TradingView
Capricor Therapeutics Rises as FDA Lifts Complete Response Letter, Resumes Review - marketscreener.com
Capricor Therapeutics Sees Surge in Trading Volume - National Today
Capricor Therapeutics (NASDAQ:CAPR) Sees Strong Trading VolumeShould You Buy? - MarketBeat
Jones Trading reiterates Capricor stock Buy on FDA review resumption By Investing.com - Investing.com Canada
HC Wainwright Reiterates Buy Rating for Capricor Therapeutics (C - GuruFocus
Capricor Advances Deramiocel BLA Review for Duchenne DMD - TipRanks
Capricor Therapeutics stock surges on FDA BLA review resumption - Investing.com
Capricor Therapeutics (NASDAQ:CAPR) Given "Buy" Rating at HC Wainwright - MarketBeat
Nio, Zevra Therapeutics, Vertex Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday - Benzinga
Capricor resumes FDA BLA review for Deramiocel; PDUFA date set for Aug 22, 2026 - TradingView
FDA sets new Deramiocel PDUFA date for Capricor (NASDAQ: CAPR) - Stock Titan
Capricor Therapeutics Stock Jumps As FDA Resumes Deramiocel Review - Benzinga
FDA Resumes Review of Capricor Therapeutics' (CAPR) Deramiocel A - GuruFocus
Capricorgains FDA reviews rejected cell therapy (CAPR:NASDAQ) - Seeking Alpha
Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA - Bitget
Capricor Therapeutics, Inc. resumes Deramiocel BLA review as FDA sets August 22, 2026 deadline - Traders Union
Capricor Therapeutics Announces Resumption of FDA BLA Review for Deramiocel in Duchenne Muscular Dystrophy Following Positive Phase 3 Results - Quiver Quantitative
FDA resumes review of Duchenne drug Deramiocel, sets Aug. 22 deadline - Stock Titan
Xenon hits a ‘home run’ in epilepsy; FDA restarts review of Duchenne cell therapy - Yahoo Finance
Biotech Stocks Pop After CBER Chief ExitModerna (NASDAQ:MRNA) - Benzinga
Capricor Therapeutics (NASDAQ:CAPR) Shares Gap UpStill a Buy? - MarketBeat
Capricor Therapeutics Stock Rises Ahead of March 12 Update as FDA Watch on Duchenne Drug Builds - TechStock²
Capricor Therapeutics to Present Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Update on March 12 - The Manila Times
Capricor Therapeutics to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026 - Quiver Quantitative
A Look At Capricor Therapeutics (CAPR) Valuation As FDA Tightens Expedited Approval Pathway - Sahm
Capricor Therapeutics Stock Pre-Market (+12%): 91-Day Insider Lock-Up Period Expires - Trefis
CAPR Stock In Spotlight As Investors Eye Next Week’s DMD Trial Data Showing Muscle And Cardiac Gains - Stocktwits
Capricor Therapeutics Poised for Breakthrough as HOPE-3 Trial Results Loom - timothysykes.com
Capricor Therapeutics (NASDAQ:CAPR) Trading Up 6.2%Here's What Happened - MarketBeat
Capricor Therapeutics Stock Jumps After-Hours As Retail Cheers Fresh FDA Attempt After Duchenne Therapy Rejection - Stocktwits
HOPE On The Horizon: Capricor To Present Deramiocel Data At The MDA Conference - RTTNews
CAPR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Capricor (CAPR) Faces Challenges Amidst Stricter FDA Approval Pr - GuruFocus
Register: Aligning With the FDA on a Regulatory Pathway To Avoid Decision Day Surprises - BioSpace
(CAPR) Volatility Zones as Tactical Triggers - Stock Traders Daily
CAPR Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Capricor Therapeutics, Inc. (CAPR) Stock Analysis: Unpacking The 82% Potential Upside - DirectorsTalk Interviews
Capricor Therapeutics (CAPR) Schedule 13G: Suvretta reports 6.6% stake - Stock Titan
A Look At Capricor Therapeutics (CAPR) Valuation As Key Deramiocel Phase 3 Milestones Advance FDA Review - simplywall.st
Capricor Therapeutics Announces Late-Breaking Presentation at 2026 MDA Clinical and Scientific Conference - Bitget
Capricor Or Sarepta: Two DMD Stocks Enter A High-Stakes Week – Which One Has More Upside? - Asianet Newsable
1.76%
0.09%
大文字化:
|
ボリューム (24 時間):